Moderna names Catalent as manufacturing partner for potential COVID-19 vaccine

[June 25, 2020]  (Reuters) - Moderna Inc <MRNA.O> said on Thursday it has partnered with contract drugmaker Catalent Inc <CTLT.N> to produce 100 million doses of its experimental COVID-19 vaccine starting in the third quarter of 2020.

Under the deal, Catalent would also provide packaging and labeling, storage and distribution services to support Moderna's late-stage clinical trial for the vaccine. (https://reut.rs/384fCLt)

(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shailesh Kuber)

[© 2020 Thomson Reuters. All rights reserved.]

Copyright 2020 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.